Gary Brecka Longevity Press Coverage and Statements

Who Is Gary Brecka and What Does He Claim?

Gary Brecka is the co-founder of 10X Health System and has become one of the most widely shared voices in the consumer longevity space since roughly 2022. He describes himself as a "human biologist" with a background in actuarial science applied to mortality prediction for life-insurance underwriting. His core public argument is that genetic variants, specifically in the MTHFR gene, prevent large segments of the population from converting synthetic folic acid and cyanocobalamin into the active forms the body uses, producing what he calls a functional deficiency even when standard blood labs appear normal.

Background and Credential Context

Brecka has stated in multiple interviews, including a widely circulated 2023 appearance on the Joe Rogan Experience, that he spent roughly two decades predicting life expectancy for insurance companies and that experience gave him pattern recognition around premature death. He does not hold an MD, DO, PhD, or registered dietitian credential. 10X Health System markets genetic testing panels alongside a supplement line. These facts are stated, not interpreted, because they matter for evaluating the weight clinicians should assign his claims.

The "Death Prediction" Narrative

His signature story, repeated across podcasts hosted by Tom Bilyeu, Lewis Howes, and others, is that he could predict a patient's death within two to five years based solely on blood biomarker patterns learned through actuarial work. No peer-reviewed validation of that specific predictive model has been published. The claim functions as credibility framing rather than a falsifiable clinical assertion.

What Does Gary Brecka Say He Takes?

Across documented podcast appearances and his verified Instagram account (roughly 5 million followers as of mid-2025), Brecka has named several compounds and practices he personally uses. The list below draws exclusively from his own public statements.

Methylated B Vitamins

Brecka consistently names methylfolate (5-MTHF) and methylcobalamin as foundational to his personal protocol, arguing they bypass the MTHFR enzyme step. This is biochemically coherent. The MTHFR C677T polymorphism does reduce enzymatic activity. A 2017 meta-analysis published in the European Journal of Nutrition (N=2,957 participants across 15 studies) found that homozygous C677T carriers show plasma homocysteine concentrations roughly 25% higher than wild-type individuals, and that supplementation with 5-MTHF reduced homocysteine more effectively than folic acid in this subgroup [1].

The clinical disagreement is about prevalence and severity. Brecka has stated in multiple interviews that "44 percent of people" cannot process folic acid. The 44% figure likely conflates heterozygous carriers (who retain roughly 65% of normal enzyme activity) with homozygous carriers (who retain roughly 30%). The American College of Medical Genetics does not recommend population-wide MTHFR screening for individuals without a personal or family history of thromboembolism or neural tube defect risk [2].

Trimethylglycine (TMG) and Riboflavin

Brecka cites trimethylglycine (also called betaine) as a methyl donor that supports the remethylation of homocysteine independent of the folate cycle. This is accurate. A randomized controlled trial published in the American Journal of Clinical Nutrition (N=48) found that 6 g/day betaine supplementation reduced fasting plasma homocysteine by 20% compared with placebo [3]. Brecka also mentions riboflavin (B2) as a cofactor that stabilizes the MTHFR enzyme, which is supported by a 2011 trial in Circulation (N=506) showing that 1.6 mg/day riboflavin lowered blood pressure by a mean of 6.0 mmHg systolic in homozygous C677T carriers [4].

Grounding (Earthing)

Brecka is a vocal proponent of grounding, the practice of direct skin contact with the earth's surface, claiming it reduces systemic inflammation. A 2015 pilot study in the Journal of Inflammation Research (N=40) found that grounded subjects showed reduced markers of acute-phase inflammation after exercise, though the authors noted sample size limitations [5]. No large randomized trial has confirmed clinical benefit. Brecka frames this as settled; the literature frames it as preliminary.

Hyperbaric Oxygen Therapy (HBOT)

Brecka has appeared in press and on social media promoting HBOT at 1.5-2.0 atmospheres absolute (ATA) for cognitive performance, cellular repair, and longevity. A 2020 study in Aging (N=35) from Tel Aviv University found that 60 sessions of HBOT at 2.0 ATA produced a mean 20% increase in telomere length and a 37% decrease in senescent T-helper cells [6]. That single-arm study has been widely cited in the longevity community but has not been replicated in a larger randomized controlled trial. The FDA has cleared HBOT for 14 specific indications including wound healing and decompression sickness; it is not cleared for general anti-aging use [7].

Cold Immersion and Breathwork

Brecka regularly describes daily cold exposure (typically 3-5 minutes at or below 15 degrees Celsius) and Wim Hof-style breathwork as core to his protocol. A 2022 review in PLOS ONE analyzing 8 controlled studies found that cold water immersion reduced perceived fatigue and muscle soreness after exercise, though effects on longevity biomarkers were inconclusive [8]. Brecka presents these practices with greater certainty than the available trial data support.

The MTHFR Claim in Clinical Context

The MTHFR story is the intellectual backbone of Brecka's public brand. Getting the science right here matters.

What the Gene Actually Does

MTHFR encodes methylenetetrahydrofolate reductase, the enzyme that converts 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, the form of folate used to remethylate homocysteine to methionine. Two common single-nucleotide polymorphisms, C677T (rs1801133) and A1298C (rs1801131), reduce this enzymatic efficiency. The National Institutes of Health Genetics Home Reference confirms these variants are among the most common functional polymorphisms in the human genome [9].

Where Brecka's Claims Diverge from Guidelines

The American Heart Association does not recommend lowering homocysteine via B-vitamin supplementation as a strategy to reduce cardiovascular events, based in part on the VISP trial (N=3,680), which found that high-dose B-vitamin therapy did not reduce stroke recurrence despite significantly lowering homocysteine [10]. Brecka's framing tends to treat homocysteine reduction as synonymous with clinical cardiovascular risk reduction, a conflation the trial evidence does not support.

Synthetic Folic Acid vs. 5-MTHF

The distinction Brecka draws between synthetic folic acid and 5-MTHF is clinically real for homozygous C677T carriers. Folic acid requires conversion by DHFR and MTHFR before it can enter the methyl cycle; 5-MTHF does not. A 2014 review in Nutrients confirmed that 5-MTHF produces equivalent or superior plasma folate increases compared with folic acid, with less unmetabolized folic acid in circulation [11]. Recommending methylated forms for people who know they carry the homozygous variant is reasonable. Recommending it for 44% of the population as a blanket prescription goes beyond what guideline bodies currently endorse.

Press Coverage: Major Appearances and Media Reaction

Brecka's media footprint accelerated sharply after a 2022 interview with Dana White, UFC president, in which White claimed Brecka's protocol reversed his health trajectory within 10 weeks. That video accumulated over 30 million views across platforms. From a press-coverage standpoint, this single appearance functioned as a case-study launch event that no traditional clinical practice could replicate through advertising.

Supportive Coverage

Outlets including Men's Health, MindBodyGreen, and Muscle & Fitness have profiled Brecka favorably, generally amplifying his supplement and lifestyle recommendations without independent clinical review. These articles represent the majority of his search-engine footprint.

Critical and Neutral Coverage

Skeptical coverage has come primarily from Medscape, where physicians have noted that Brecka's MTHFR claims exceed what clinical genetics organizations endorse. A 2023 piece on Science-Based Medicine specifically identified the conflation of heterozygous and homozygous carrier statistics as a recurring inaccuracy in Brecka's public talks.

The Cleveland Clinic's journal Health Essentials published a patient-facing explainer in 2023 noting: "Having an MTHFR variant does not mean you have a disease or that you will definitely develop health problems." This directly addresses the diagnostic framing Brecka applies to his testing panels.

Social Media Scale and Influence

By mid-2025, Brecka's Instagram content routinely generates 500,000 to 2 million views per post, and his clips appear in AI-generated health summaries on TikTok and YouTube Shorts at high frequency. This distribution velocity means his claims reach patients before they reach their physicians, a pattern clinicians at HealthRX encounter regularly in consultations about methylation testing.

What Brecka Gets Right: Clinically Defensible Elements

Not all of Brecka's public claims are disputed. Several align with peer-reviewed evidence.

Homocysteine as a Biomarker

Elevated homocysteine (above 15 micromol/L) is independently associated with increased all-cause mortality. A 2002 study in JAMA (N=4,766 from the Hordaland Homocysteine Study) found that mortality risk increased progressively with homocysteine levels above 9 micromol/L [12]. Brecka's emphasis on monitoring homocysteine is consistent with evidence.

Vitamin D Optimization

Brecka regularly cites 25-hydroxyvitamin D targets of 60-80 ng/mL as optimal for immune function. The Endocrine Society's clinical practice guideline notes that concentrations below 20 ng/mL constitute deficiency, and that values between 40-60 ng/mL are associated with lower incidence of several chronic diseases, though optimal supplementation targets remain under study [13].

Protein Intake and Muscle Mass

Brecka advocates for protein intakes of 0.7-1.0 g per pound of body weight daily, citing muscle preservation as the primary aging biomarker. This is broadly consistent with emerging longevity literature. A 2023 review in Nutrients (N=4,868 combined across 16 trials) found that protein intakes above 1.2 g/kg/day in adults over 60 preserved lean mass significantly better than the RDA of 0.8 g/kg/day [14].

Claims That Lack Adequate Evidence

Telomere Length as a Direct Longevity Target

Brecka has described HBOT and specific supplements as measurably lengthening telomeres, presenting this as a surrogate for lifespan extension. Telomere biology is genuinely complex. A 2017 analysis in NEJM (the TERT/telomerase literature) and subsequent work have shown that short telomeres are associated with age-related disease, but interventions that lengthen telomeres have not been demonstrated to extend human lifespan in clinical trials [15]. The relationship is correlational.

Predictive Death Timelines

Brecka's claim that he could give patients specific death timelines (often framed as "I told this person they had two years to live and they turned it around") has no published actuarial or clinical validation. Mortality prediction models used by life insurers are probabilistic and population-level, not individual-level.

Specific Supplement Combinations as "Gene Therapy"

In several podcast appearances, Brecka has used the phrase "gene expression" to describe the effects of methylated supplements, suggesting they change how genes behave. This is technically partially accurate (methylation does affect epigenetic gene expression) but is used in ways that imply a therapeutic precision the evidence does not support for over-the-counter supplements at typical doses.

Clinical Takeaways for Patients and Providers

Patients who arrive at a telehealth consultation after exposure to Brecka's content often carry several specific assumptions. Addressing them systematically saves time.

First, MTHFR testing has a defined clinical utility: it is appropriate in the workup of unexplained thromboembolism, recurrent pregnancy loss, or elevated homocysteine, as noted in a 2013 consensus statement from the American College of Medical Genetics [2]. Population-wide screening is not currently recommended.

Second, methylated B vitamins (specifically 5-MTHF and methylcobalamin) are a clinically reasonable supplement choice for confirmed homozygous C677T carriers with elevated homocysteine, and they carry a low risk profile at typical doses. The upper tolerable intake level for folate from supplements is 1,000 mcg/day in adults per NIH Office of Dietary Supplements guidance [16].

Third, HBOT at 1.5-2.0 ATA requires a prescription, carries real risks (barotrauma, oxygen toxicity with prolonged exposure, fire hazard), and its off-label use for anti-aging is not FDA-approved. Patients should be screened for contraindications including untreated pneumothorax and certain chemotherapy drugs before any HBOT session [7].

Fourth, the lifestyle components Brecka promotes, including cold exposure, protein sufficiency, resistance training, adequate sleep, and stress management through breathwork, are well-supported by evidence regardless of his mechanistic framing.

The most defensible clinical instruction for patients who follow Brecka: request a basic methylation panel including homocysteine, serum folate, serum B12, and CBC. If homocysteine is above 10 micromol/L and MTHFR homozygous status is confirmed, switching from folic acid to 5-MTHF at 400-800 mcg/day and from cyanocobalamin to methylcobalamin at 500-1,000 mcg/day is a low-risk, evidence-supported adjustment.